Acute STEMI, first hours | Primary PCI versus MT (fibrinolysis) | Multiple studies; >14 000 pts in total [6] | Death, recurrent MI, late revascularisation; PCI better |
Heart failure, LVEF <35% | ICD versus MT | MADIT, MADIT II, COMPANION, SCD-HeFT; >5000 pts [7] | Death, sudden death; ICD better |
Heart failure, LVEF <35%, LBBB, QRS >120 ms | CRT±ICD versus MT | CARE-HF, COMPANION | Death, heart failure hospitalisations; CRT better |
Heart failure, LVEF <35%, LBBB, QRS >120 ms | CRT combined with ICD versus ICD | RAFT; >4000 pts [7] | CRT better |
Refractory heart failure, ineligible for HTx | LVAD versus MT | REMATCH; 129 pts [8] | Death; LVAD better |
Aortic stenosis, ineligible for surgery | TAVI versus MT | PARTNER B; 358 pts [9] | Death; TAVI better |
Aortic stenosis, high surgical risk | TAVI versus surgical AVR | PARTNER A, CORE-VALVE US; ∼1500 pts [10] | Death; no significant differences |
Degenerative/ functional mitral regurgitation, eligible for surgery | Percutaneous repair# versus surgical treatment | EVEREST II; 279 pts [11] | Death or late MV surgery; surgical treatment better (no differences for death) |
Permanent AF | Catheter ablation versus MT | Various; ∼550 pts [12] | Recurrent AF: catheter ablation better |
Patent PFO and prior stroke/TIA | Percutaneous PFO closure versus MT | CLOSURE, PC trial, RESPECT; ∼2300 pts [5] | Death or stroke (±TIA, peripheral embolism); no significant differences |
Drug-resistant hypertension | Renal artery denervation versus MT, open | Symplicity HTN-2; 106 pts [13] | BP reduction; renal artery denervation better |
Drug-resistant hypertension | Renal artery denervation versus MT, patient blinded | Simplicity HTN-3, DENERHTN; ∼2000 pts [13] | BP reduction; no significant differences |